Literature DB >> 16484643

Additional causes for distal sensory polyneuropathy in diabetic patients.

K C Gorson1, A H Ropper.   

Abstract

OBJECTIVE: To assess the frequency of additional causes of distal sensory polyneuropathy (DSP) in patients with diabetes mellitus (DM).
METHODS: Retrospective review of patients with DM and DSP during a 5 year period. A quantitative sensory score (QSS) was determined at the initial evaluation and extensive laboratory and EMG studies were performed. Patients with one or more potential causes for DSP were compared to those with DM alone.
RESULTS: Fifty five patients (53%) had potential additional causes for DSP. These included: neurotoxic medications (seven), alcohol abuse (six), and B12 deficiency and renal disease (four each). The most common laboratory abnormalities were: abnormally low levels of vitamin B6 (11) or B1 (10), monoclonal gammopathy (eight), and hypertriglyceridaemia (eight). Twenty six (25%) subjects had more than one additional cause. Nine (9%) had three or more demyelinating features on EMG. There was a trend toward a lower QSS score (p = 0.05) and reduced mean amplitude of the sensory potentials in those with additional causes. Those with additional causes more often had upper limb sensory symptoms (p = 0.001) and sensory findings (p = 0.003).
CONCLUSION: There was a high frequency of additional sources of DSP in patients with DM. These patients more often had sensory symptoms and findings in the hands. Tests that may be useful in the evaluation of DSP in diabetic patients include measures of vitamins B1, B6, B12, serum triglycerides, and immunofixation.

Entities:  

Mesh:

Year:  2006        PMID: 16484643      PMCID: PMC2077706          DOI: 10.1136/jnnp.2005.075119

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  32 in total

Review 1.  Evaluating patients with suspected peripheral neuropathy: do the right thing, not everything.

Authors:  Rahman Pourmand
Journal:  Muscle Nerve       Date:  2002-08       Impact factor: 3.217

Review 2.  Distal symmetric polyneuropathy: a definition for clinical research: report of the American Academy of Neurology, the American Association of Electrodiagnostic Medicine, and the American Academy of Physical Medicine and Rehabilitation.

Authors:  J D England; G S Gronseth; G Franklin; R G Miller; A K Asbury; G T Carter; J A Cohen; M A Fisher; J F Howard; L J Kinsella; N Latov; R A Lewis; P A Low; A J Sumner
Journal:  Neurology       Date:  2005-01-25       Impact factor: 9.910

3.  Guidelines in electrodiagnostic medicine. Consensus criteria for the diagnosis of partial conduction block.

Authors:  R K Olney
Journal:  Muscle Nerve Suppl       Date:  1999

4.  Antibody panels in idiopathic polyneuropathy and motor neuron disease.

Authors:  G I Wolfe; W H El-Feky; J S Katz; W W Bryan; F H Wians; R J Barohn
Journal:  Muscle Nerve       Date:  1997-10       Impact factor: 3.217

5.  Improvement in chronic ischemic neuropathy after intramuscular phVEGF165 gene transfer in patients with critical limb ischemia.

Authors:  D Simovic; J M Isner; A H Ropper; A Pieczek; D H Weinberg
Journal:  Arch Neurol       Date:  2001-05

6.  Alcoholic neuropathy is clinicopathologically distinct from thiamine-deficiency neuropathy.

Authors:  Haruki Koike; Masahiro Iijima; Makoto Sugiura; Keiko Mori; Naoki Hattori; Hiroki Ito; Masaaki Hirayama; Gen Sobue
Journal:  Ann Neurol       Date:  2003-07       Impact factor: 10.422

7.  Neuropathy associated with hyperlipidemia.

Authors:  P G McManis; A J Windebank; M Kiziltan
Journal:  Neurology       Date:  1994-11       Impact factor: 9.910

8.  The prevalence by staged severity of various types of diabetic neuropathy, retinopathy, and nephropathy in a population-based cohort: the Rochester Diabetic Neuropathy Study.

Authors:  P J Dyck; K M Kratz; J L Karnes; W J Litchy; R Klein; J M Pach; D M Wilson; P C O'Brien; L J Melton; F J Service
Journal:  Neurology       Date:  1993-04       Impact factor: 9.910

9.  A controlled investigation of the cause of chronic idiopathic axonal polyneuropathy.

Authors:  R A C Hughes; T Umapathi; I A Gray; N A Gregson; M Noori; A S Pannala; A Proteggente; A V Swan
Journal:  Brain       Date:  2004-06-16       Impact factor: 13.501

10.  Polyneuropathy associated with monoclonal gammopathy of undetermined significance. A prospective study of the prognostic value of clinical and laboratory abnormalities.

Authors:  N C Notermans; J H Wokke; H M Lokhorst; H Franssen; Y van der Graaf; F G Jennekens
Journal:  Brain       Date:  1994-12       Impact factor: 13.501

View more
  5 in total

Review 1.  [Diabetic neuropathy: do not only consider distal symmetrical neuropathy].

Authors:  K Doppler; K Reiners
Journal:  Nervenarzt       Date:  2015-02       Impact factor: 1.214

Review 2.  Not all neuropathy in diabetes is of diabetic etiology: differential diagnosis of diabetic neuropathy.

Authors:  Roy Freeman
Journal:  Curr Diab Rep       Date:  2009-12       Impact factor: 4.810

3.  High prevalence of low plasma thiamine concentration in diabetes linked to a marker of vascular disease.

Authors:  P J Thornalley; R Babaei-Jadidi; H Al Ali; N Rabbani; A Antonysunil; J Larkin; A Ahmed; G Rayman; C W Bodmer
Journal:  Diabetologia       Date:  2007-08-04       Impact factor: 10.122

4.  Association between Iron Intake and Diabetic Peripheral Neuropathy in Type 2 Diabetes: Significance of Iron Intake and the Ratio between Iron Intake and Polyunsaturated Fatty Acids Intake.

Authors:  Kyuho Kim; YoonJu Song; Tae Jung Oh; Sung Hee Choi; Hak Chul Jang
Journal:  Nutrients       Date:  2020-11-01       Impact factor: 5.717

5.  Comparison of diabetic and idiopathic sensory polyneuropathies with respect to nerve fibre affection and risk factors.

Authors:  Mustapha Itani; Sif Gylfadottir; Thomas Krøigård; Laura Gaist; Jakob Vormstrup Holbech; Alexander Gramm Kristensen; Pall Karlsson; Sören Möller; Hatice Tankisi; David Gaist; Troels S Jensen; Nanna Brix Finnerup; Søren Hein Sindrup
Journal:  BMJ Neurol Open       Date:  2022-03-14
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.